Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Takeda, DNDi to Collaborate in Visceral Leishmaniasis Drug Development
April 6, 2018
- Daiichi Sankyo Expands Cancer Collaboration with DarwinHealth
April 6, 2018
- Takeda to Divest Its Brazilian OTC, Gx Subsidiary to Local Pharma
April 6, 2018
- Zyprexa Generics Now Carry Same Indications as Originator
April 5, 2018
- Nebulized COPD Med Lonhala Magnair Now Available in US: Sunovion
April 5, 2018
- Nichi-Iko to Raise 21.2 Billion Yen for Elmed Eisai Buyout
April 5, 2018
- Nihon Medi-Physics’ Project to Develop Labeled Antibody Therapeutics Selected for AMED’s CiCLE Grant Program
April 4, 2018
- Mochida Targets Sales of 103 Billion Yen in FY2020, Adding Gastroenterology to Priority Fields: New Biz Plan
April 4, 2018
- Fycompa Filed for Label Expansion in US for Pediatric Epilepsy
April 3, 2018
- Sanofi Seeks Asthma Indication for Dupixent in Japan
April 3, 2018
- Kyorin Nabs Rights to Sanwa Kagaku’s Nocturia Drug in Japan, Asia
April 3, 2018
- Apomorphine Sublingual Film Filed in US: Sunovion
April 3, 2018
- Daiichi Sankyo Alters Terms of Settlement over US Olmesartan Products Liability Litigation
April 3, 2018
- Ambicion Obtains Global Rights to RIKEN’s NKT Cell-Targeted Anti-Cancer Therapy
April 3, 2018
- Shionogi Trio Puts Up Add’l 1.8 Billion Yen Each for Peptide Therapeutics JV
April 2, 2018
- Zeria Files Iron Deficiency Med in Japan
April 2, 2018
- Nippon Kayaku Notches Top Court Victory for Elplat Damages Suit Too
April 2, 2018
- Kihito Takahashi Tapped as EVP of GSK Japan
April 2, 2018
- Lynparza Companion Diagnostic Approved in Japan: AZ
April 2, 2018
- Keytruda Filed for Tumor-Agnostic Indication in Japan
April 2, 2018
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…